Top
image credit: Adobe Stock

Takeda grabs ex-China fruquintinib rights from Hutchmed

January 23, 2023

Category:

Takeda has taken rights outside China, Hong Kong and Macau to Hutchmed’s colorectal cancer therapy fruquintinib, a small molecule vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3 taken as a once daily pill that is in late-stage development in the US, Europe and Japan with filings due later this year.

Fruquintinib has already been approved in China – under the Elunate brand name – becoming the country’s first home-grown therapy for a major form of cancer back in 2018. It is partnered in China with Eli Lilly.

Read More on Pharmaphorum